Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Broad-spectrum coverage is on your side

Tigecycline (Tygacil®) has in vitro activity against a wide range of range of pathogens1,2

  • Tigecycline is indicated in adults and in children from the age of 8 years for the treatment of complicated intra-abdominal infections and complicated skin and soft tissue infections excluding diabetic foot infections1

  • Tigecycline should be used only in situations where other alternative antibiotics are not suitable1 

Tygacil® has broad in vitro* activity, including many resistant pathogens2

Full preview Tygacil has broad in vitro activity

Adapted from Wilcox 2006.2

*In vitro activity does not necessarily correlate with clinical results.
†Except Proteus spp. and Providencia spp.
‡Includes MRSA and glycopeptide-resistant enterococci (GRE).
§Includes ESBL-producing bacteria and Acinetobacter spp. Please refer to SmPCs of individual antibiotics for specific coverage

Tigecycline (Tygacil ®) overcomes most known tetracycline resistance mechanisms3

Tigecycline inhibits bacterial protein synthesis in the 30S ribosomal subunit.1,4

Tigecycline:

  • is five times more stable binding with the ribosome than tetracycline3,4

  • overcomes the two major tetracycline resistance mechanisms (ribosomal protection and efflux pumps)1

  • is not affected by extended-spectrum beta-lactamases5

References

  1. Tygacil Summary of Product Characteristics
  2. Wilcox M H. Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect (Larchmt) 2006;7:69-80
  3. Bauer G, Berens C et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-599
  4. Bergeron J, Ammirati M et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-2228
  5. European Medicines Agency. Tygacil European public assessment report (EPAR) report. 2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ _Scientific_Discussion/human/000644/WC500044511.pdf. Accessed August 2015